The GSC is a department of the BC Cancer Research Institute and a high-throughput genome sequencing facility. We are leaders in genomics, proteomics and bioinformatics in pursuit of novel treatment strategies for cancers and other diseases.
Among the world’s first genome centres to be established within a cancer clinic, for more than two decades our scientists and innovators have been designing and deploying cutting-edge technologies to benefit health and advance clinical research.
Among the GSC’s most significant accomplishments are the first publication to demonstrate the use of whole-genome sequencing to inform cancer treatment planning, the first published sequence of the SARS coronavirus genome and major contributions to the first physical map of the human genome as part of the Human Genome Project.
By joining the GSC you will become part of an exceptional and diverse team of scientists, clinicians, experts and professionals operating at the leading edge of clinical research. We look for people who share our core values—science, timeliness, respect—to join us on our mission to use genome science for the betterment of health and society.
Job Reference No: PDF_01553_Sadar Lab_2021_12_24
The laboratory of Dr. Marianne Sadar located within the Genome Sciences Centre within the BC Cancer Research Centre, in Vancouver, British Columbia, Canada has an opening for a post-doctoral fellow to work on a project involving application of novel antagonists of androgen receptor as imaging agents and therapeutics. The Sadar lab mainly focuses on the development of small molecules for castration resistant prostate cancer (CRPC) that bind to the intrinsically disordered N-terminal domain (NTD) of androgen receptor (AR). The work is precedent in the entire field of steroid hormone receptors, with no other small molecule inhibitor reported to bind to the N-terminus of any other steroid hormone receptor.
The successful candidate will join an ongoing collaboration with Dr. Raymond Andersen (drug design and synthesis), Dr. Lin (Chemistry and synthesis of PET imaging agen), and Dr. Strynadka (structural biology) to study the new generation of small molecule inhibitor binding to the N-terminus of steroid hormone receptor, and is expected to conduct laboratory research to design and interpret experiments using proteomic, molecular, biochemical, and genomic tools to thoroughly and robustly quantify changes affecting prostate cancer cell lines/tumor xenografts in response to the new small molecule inhibitor.
The successful scientist will join the laboratory of Dr. Sadar, located in state-of-the-art BC Cancer Research Centre. This is a world-class center for translational cancer research. There are many highly functioning integrated platforms for both basic and translational research such as BC Genome Sciences Centre, the Centre for Translational and Applied Genomics, and the Centre of Excellence for Functional Cancer Imaging, and a superbly equipped proteomics facility.
The desirable candidate should have experience in molecular biology, mammalian cell culture, and use of genomic tools. Experience with data analysis for large datasets will be beneficial to the candidate.
Please submit a detailed cover letter and resume to firstname.lastname@example.org, using Job Reference No: PDF_01553_Sadar Lab_2021_12_24 in the subject line of your email.
This posting will remain online until filled.
Due to current COVID-19 restrictions, the position would require working remotely on a temporary basis. This restriction would be re-evaluated upon re-contracting.
We believe that equity, diversity and inclusivity are essential for the advancement of human knowledge and science.
We welcome all applicants and provide all employees with equal opportunity for advancement, regardless of race, colour, ancestry, place of origin, political belief, religion, marital status, family status, physical or mental disability, sex, sexual orientation, gender identity or expression, age, conviction of a criminal or summary conviction offence unrelated to their employment.
All qualified candidates are encouraged to apply; however, Canadian citizens and permanent residents will be given priority.